Full Press Release Details
Biogen Issues Statement in Response to the Passing of Charles Weissmann, MD, Ph.D., Co-Founder of Biogen.
BIIB
Biogen Issues Statement in Response to the Passing of Charles Weissmann, MD, Ph.D., Co-Founder of Biogen
Key Takeaway: Biogen Issues Statement in Response to the Passing of Charles Weissmann, MD, Ph.D., Co-Founder of Biogen
Price reaction · baseline $174.8 (2025-12-19 close) · clean, no other BIIB news in the window
day 0 close · peak
-0.1%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+34%
120-day peak, hindsight
Typical move
1.8%
average across 15 past catalysts
Lead asset
Alefacept
Phase 3 · Chronic Plaque Psoriasis